



DT05 Rec'd PCT/PTO 21 OCT 2002

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4

In re Application of: Austen John Woolfe
Serial No.: 10/089,599
Filing Date: 29 March 2002
Docket Number: NHC202119US
Title: ANTI-INFLAMMATORY
PHARMACEUTICAL PREPARATIONS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97(c) hereby submit these publications for the Examiner's consideration which are known to them and considered warranting disclosure under 37 C.F.R. §1.56. A full copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands the Examiner will make an independent evaluation of the cited publications.

U.S.S.N. 10/089,599

Page -2-

No additional costs are believed to be due in connection with the filing of this disclosure. However, please charge any necessary fees to our Deposit Account No. 50-0943.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,



Simona A. Levi-Minzi, Ph.D.

Attorney for Applicants

Registration No. 43,750

IVAX CORPORATION
4400 Biscayne Boulevard
Miami, Florida 33137
Tel.: (305) 575-6061
Fax.: (305) 575-6064

Date: 10/17/02

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 10/12/02

By:



Jared G. Silberhorn

+

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

7

Application Number

10/089,599

Filing Date

29 March 2002

First Named Inventor

Woolfe, John

Group Art Unit

Examiner Name

Attorney Docket Number

NHC202119US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		.	WO00/01368		Woolfe, A.J.	01-13-2000		
		.	WO00/15200		Woolfe, A.J.	03-23-2000		
		.	WO00/56339		Pharmascience, Inc.	09-28-2000		
		c	EP1020182		Sherman, B.C.	07-19-2000		
		.	EP1068867		Sherman, B.C.	01-17-2001		
		.	WO91/16895		Searle & Co.	11-14-1991		
		.	WO91/16886		Searle & Co.	11-14-1991		

Examiner
Signature

Date _____

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**